文摘
Introduction: The efficacy of the treatment of allergic disease by inhibition of the interaction between IgE and its high affinity receptor (Fc?RI) by monoclonal anti human IgE antibodies has been demonstrated in clinical trials (1). In vivo vaccination with large fragments of human IgE encounters two problems: (a) the generation of an anaphylactogenic immune response supposed to cause severe side effects and (b) the expected low immunogenicity of these autoantigen-derived IgE fragments in humans. The monoclonal anti human IgE antibody BSW17 recognizes IgE in solution thereby inhibiting receptor attachment but also binds to Fc?RIα-bound IgE (2). However, BSW17 is non anaphylactogenic. Here we present a strategy, based upon peptides (mimotopes) mimicking the natural epitope of BSW17, leading to immunogens expected to represent “semi-foreign” structures to the human immune system still being able to elicit the generation of a specific anti human IgE response.